Medigene AG
MediGene AG english
MediGene settles patent dispute with the Loyola University and MedImmune
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
MediGene settles patent dispute with the Loyola University and MedImmune
Martinsried/San Diego, January 9, 2003 MediGene AG (Neuer Markt: MDG), a
German-U.S. biotech company, announced today that it has settled its legal
dispute with the Loyola University of Chicago and MedImmune Inc. relating to
contested ownership rights in the CVLP technology. The settlement dismisses all
claims to damages against MediGene by Loyola and MedImmune and terminates
MediGene’s appeal against the lower court judgment granting the contested
ownership rights to Loyola.
The CVLP technology is a method for the creation of virus-like particles that
MediGene employs for the development of a tumor vaccine to treat cervical
carcinoma and its precursors. As a result of the settlement announced today, a
license from Loyola will be required if the vaccine is marketed. MediGene holds
patents unaffected by the settlement on portions of the vaccine to protect it
from imitators.
The vaccine is in a clinical phase 1/2 study and is one of six product
candidates that MediGene is currently developing.
end of ad-hoc-announcement (c)DGAP 09.01.2003
——————————————————————————–
WKN: 502090; ISIN: DE0005020903; Index: NEMAX-50
Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, Hannover, München und Stuttgart
090830 Jän 03
Latest News
Latest Reports
No Reports found
Upcoming Events
No Events found
Webcasts
No Webcasts found